ArticleClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2021
Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign.
Article in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Article
- Sero-epidemiology and risk factor investigation for exposure to Japanese encephalitis virus in swine populations reared in climatically diverse regions of India.Tropical animal health and production · 2024Article
- Study of seroprevalence of SARS-CoV-2 in Kazakhstan.Epidemiology and infection · 2023Article
- Seroprevalence and SARS-CoV-2 invasion in general populations: A scoping review over the first year of the pandemic.PloS one · 2023Article
- Multi-dimensional factors related to participation in a population-wide mass COVID-19 testing program among Hong Kong adults: A population-based randomized survey.Social science & medicine (1982) · 2022Article
- Hope and trust: Public attitudes toward mass COVID-19 testing programs in Guangzhou, China.Frontiers in psychology · 2022Article
- Serological survey of SARS-CoV-2 in companion animals in China.Frontiers in veterinary science · 2022Article
- Risk of SARS-CoV-2 Infection Among People Living With HIV in Wuhan, China.Frontiers in public health · 2022Article
- Article
- Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020.Pathogens (Basel, Switzerland) · 2021Article
- Article
- Seroprevalence of SARS-CoV-2 antibody among individuals aged above 15 years and residing in congregate settings in Dire Dawa city administration, Ethiopia.Tropical medicine and health · 2021Article
- Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel.European journal of epidemiology · 2021Article
- Seroprevalence of SARS-CoV-2 antibodies in the poorest region of Brazil: results from a population-based study.Epidemiology and infection · 2021Article
- The prevalence of antibodies to SARS-CoV-2 among blood donors in China.Nature communications · 2021Article
- Precision shielding for COVID-19: metrics of assessment and feasibility of deployment.BMJ global health · 2021Review
- Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity.Frontiers in immunology · 2021Article
- SARS-CoV-2 Seroprevalence and Profiles Among Convalescents in Sichuan Province, China.Frontiers in public health · 2021Article
- Article
- Seroprevalence of SARS-CoV-2 infections among children visiting a hospital.Pediatric investigation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe outbreak of the 2019 coronavirus disease (COVID-19) pandemic in Wuhan, China, has subsided after being hard hit by the disease and subsequent city lockdown. Information on the number of people involved in Wuhan is still inadequate. This study aimed to describe the screening results of 61 437 community members in Wuchang District, Wuhan.
methodsIn mid-May 2020, Wuhan launched a population-scale city-wide SARS-CoV-2 testing campaign, which aimed to perform nucleic acid and viral antibody testing for citizens in Wuhan. Here we show the screening results of cluster sampling of 61 437 residents in Wuchang District, Wuhan, China.
resultsA total of 1470 (2.39%, 95% CI 2.27-2.52) individuals were detected positive for at least one antiviral antibody. Among the positive individuals, 324 (0.53%, 95% CI 0.47-0.59) and 1200 (1.95%, 95% CI 1.85-2.07) were positive for immunoglobulin IgM and IgG, respectively, and 54 (0.08%, 95% CI 0.07-0.12) were positive for both antibodies. The positive rate of female carriers of antibodies was higher than those of male counterparts (male-to-female ratio of 0.75), especially in elderly citizens (ratio of 0.18 in 90+ age subgroup), indicating a sexual discrepancy in seroprevalence. In addition, viral nucleic acid detection using real-time PCR had showed 8 (0.013%, 95% CI 0.006-0.026) asymptomatic virus carriers. DISCUSSION: The seroprevalence of SARS-CoV-2 in Wuhan was low. Most Wuhan residents are still susceptible to this virus. Precautions, such as wearing mask, frequent hand hygiene and proper social distance, are necessary before an effective vaccine or antiviral treatments are available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.